ConductScience.org, home

Comparison · NCT02265796-98d5cd91

Ranolazine vs Sugar Pill: Ischemia Driven Revascularization or Hospitalization

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ranolazine vs Sugar Pill: Ischemia Driven Revascularization or Hospitalization. Trial comparisons, record NCT02265796-98d5cd91. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02265796-98d5cd91

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.120.04170.3wilson
Risk in group 20.20.08860.391wilson
Risk difference, group 1 minus group 2-0.08-0.2870.131newcombe hybrid score
Risk ratio, group 1 over group 20.60.162.25log
Odds ratio, group 1 over group 20.5450.1152.58log
Number needed to treat, for one fewer participant with the outcome on Ranolazine than on Sugar Pill12.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ranolazine
Ranolazine 500 mg tablets~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks~Ranolazine: Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
325OG000
Group 2Sugar Pill
Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks~Sugar pill: 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks
525OG001

Outcome

Type
SECONDARY
Title
Ischemia Driven Revascularization or Hospitalization
Description
Number of participants who reported adverse events for ischemia driven revascularization or hospitalization
Time frame
4 month
Population
the incidence of ischemia driven hospitalization or catheterization was assessed for all subjects.

Source ClinicalTrials.gov

Trial

Title
Ranolazine Among Unrevascularized Chronic Stable Angina Patients
NCT number
NCT02265796
Phases
PHASE2
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Lead sponsor
North Florida Foundation for Research and Education
Results first posted
2017-12-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02265796-98d5cd91